Your browser doesn't support javascript.
loading
Prognostic Validation Using GesEPOC 2017 Severity Criteria. / Validación pronóstica según los criterios de la GesEPOC 2017.
Cabrera López, Carlos; Casanova Macario, Ciro; Marín Trigo, José María; de-Torres, Juan P; Torres, Rebeca Sicilia; González, Jesús María; Polverino, Francesca; Divo, Miguel; Pinto Plata, Víctor; Zulueta, Javier; Callejas, Francisco Javier; Celli, Bartolomé.
Afiliación
  • Cabrera López C; Servicio de Neumología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España. Electronic address: ccablopn@gmail.com.
  • Casanova Macario C; Servicio de Neumología, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, España.
  • Marín Trigo JM; Servicio de Neumología, Hospital Universitario Miguel Servet, Zaragoza, España.
  • de-Torres JP; Servicio de Neumología, Clínica Universitaria de Navarra, Pamplona, España.
  • Torres RS; Servicio de Neumología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
  • González JM; Unidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
  • Polverino F; Pulmonary and Critical Care Service, Brigham and Women's Hospital, Boston, Massachusetts, Estados Unidos.
  • Divo M; Pulmonary and Critical Care Service, Brigham and Women's Hospital, Boston, Massachusetts, Estados Unidos.
  • Pinto Plata V; Pulmonary and Critical Care Division, Baystate Medical Center, Springfield, Massachusetts, Estados Unidos.
  • Zulueta J; Servicio de Neumología, Clínica Universitaria de Navarra, Pamplona, España.
  • Callejas FJ; Complejo Hospitalario Universitario de Albacete, Albacete, España.
  • Celli B; Pulmonary and Critical Care Service, Brigham and Women's Hospital, Boston, Massachusetts, Estados Unidos.
Arch Bronconeumol (Engl Ed) ; 55(8): 409-413, 2019 Aug.
Article en En, Es | MEDLINE | ID: mdl-30718019
INTRODUCTION: The Spanish COPD guidelines (GesEPOC) have been recently modified. The aim of this study is to assess this revision and evaluate the prognosis of patients according to the new classification of severity. METHODS: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC. RESULTS: Mean age was 66±9.6 years and mean FEV1% was 59.7±20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92±0,66 vs. 0.52±1.91, p<0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p<0.001). Dyspnea and FEV1% were also independent predictors of mortality (p<0.001), and neither was inferior to the risk classification proposed by GesEPOC. CONCLUSIONS: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad Pulmonar Obstructiva Crónica Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En / Es Revista: Arch Bronconeumol (Engl Ed) Año: 2019 Tipo del documento: Article Pais de publicación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad Pulmonar Obstructiva Crónica Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En / Es Revista: Arch Bronconeumol (Engl Ed) Año: 2019 Tipo del documento: Article Pais de publicación: España